

The Contingency Management Policy & Practice Group

H. Westley Clark, MD, JD,
MPH, DFASAM
Consultant

Mady Chalk, PhD, MSW
Principal & Managing Director
The Chalk Group

Carol McDaid
Principal
Capitol Decisions, Inc.

Tyler G. Erath, PhD
NIH Postdoctoral Fellow,
University of Vermont

Michael McDonell, PhD
Professor
Washington State University

Garrett Moran, PhD
Principal
Moran Consulting

Carla Rash, PhD
Associate Professor
University of Connecticut

Richard Rawson, PhD
Emeritus Professor, UCLA
Research Professor,
University of Vermont

Sarah A. Wattenberg, LCSW-C
Director, Quality and
Addiction Services
National Association for
Behavioral Healthcare

Statement:

Members of the Contingency Management Policy Group (CMPG) and other stakeholders are very concerned with the Substance Abuse and Mental Health Services Administration's (SAMHSA) recent State Opioid Response and Tribal Opioid Response grant announcements that limit the use of funding for contingency management (CM) incentives to \$75 per patient, per budget year. Research does not support this incentive amount, which will lead to ineffective interventions that will not reduce stimulant-related overdose deaths.

Call to Action:

The CMPG calls upon SAMHSA to rescind the \$75 limit on patient incentives and re-issue these grant announcements to permit the use of evidence-based amounts for CM. Evidence-based CM could reduce stimulant-associated overdoses and save tens of thousands of lives every year.

Background:

CM is the only evidence-based treatment for stimulant use disorder (StimUD) which is involved in almost half of the country's overdoses. This policy is inconsistent with federal funding for higher CM incentives through the California 1115 waiver and with the report by the Office of the Assistant Secretary for Planning and Evaluation (November 7, 2023).